Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0013362 (
dysarthria
)
3,768
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A 68-year-old right-handed woman was admitted to Tokyo Metropolitan
Geriatric
Hospital because of slowly progressive
dysarthria
and writing disability over 2-year period. On admission, severe
dysarthria
was observed, but no dysphagia. The
dysarthria
mostly resembled a type of pseudobulbar palsy, although it was associated with effortful speech production. An oro-facial apraxia was also found. She could name objects, and could understand spoken words correctly. Examination using the Western Aphasia Battery showed diminution of word fluency, impaired repetition and perseveration and writing errors. On the Wechsler Adult Intelligence Scale-R verbal IQ was 100 and performance IQ was 87. These scores did not suggest any significant degree of general intellectual deterioration. Wisconsin card sorting test disclosed mild frontal dysfunction. Magnetic resonance imaging showed cortical atrophy in the bilateral frontal and temporal lobes. Measurements of regional cerebral metabolic rate by 18F-FDG-PET demonstrated decreased uptake in the latero-dorso-inferior area of the bilateral frontal lobes, especially on the left side. The present case showed slowly progressive
dysarthria
and progressive aphasia without generalized dementia, and without typical aphasia. These symptoms are speculated to be related to the atrophy in the bilateral frontal and temporal lobes shown by MRI and the decreased metabolic rate in the left dominant bilateral frontal lobes on PET study. The pathologic process responsible for these lesions remains obscure.
...
PMID:[Slowly progressive dysarthria and impaired language function--a case report]. 128 97
This study investigated the relationship between measures of Long-Term Average
Spectrum
(LTAS) for speakers with Parkinson's disease (PD) and Multiple Sclerosis (MS) and scaled estimates of perceived speech severity. Perceived severity was operationally defined as listeners' overall impression of voice, resonance, articulatory precision, and prosody without regard to intelligibility. Healthy control talkers were also studied. Speakers were audio recorded while reading Harvard Sentences and the Grandfather Passage. Using TF32 (Milenkovic, 2005), the LTAS was computed for sentences. Coefficients of the first four moments were used to characterize energy across the speech spectrum. Supplemental acoustic measures of articulatory rate, vocal intensity, and fundamental frequency also were obtained. Three speech-language pathologists scaled speech severity for the reading passages. Results indicated no group differences in acoustic measures. The absolute magnitude of correlations between LTAS moment coefficients and perceptual estimates of scaled severity within and across speaker groups ranged from .16 to .53, with the strongest correlations for the PD group. These results suggest that the LTAS may prove useful in conjunction with perceptual judgments to document speech spectral changes related to treatment or disease progression. Findings further suggest that different acoustic models of severity are likely needed for
dysarthria
secondary to PD and
dysarthria
secondary to MS.
...
PMID:Long-Term Average Spectral (LTAS) Measures of Dysarthria and Their Relationship to Perceived Severity. 2942 63
Estimates of the prevalence of speech and motor speech disorders in persons with complex neurodevelopmental disorders (CND) can inform research in the biobehavioural origins and treatment of CND. The goal of this research was to use measures and analytics in a diagnostic classification system to estimate the prevalence of speech and motor speech disorders in convenience samples of speakers with one of eight types of CND. Audio-recorded conversational speech samples from 346 participants with one of eight types of CND were obtained from a database of participants recruited for genetic and behavioural studies of speech sound disorders (i.e., excluding dysfluency) during the past three decades. Data reduction methods for the speech samples included narrow phonetic transcription, prosody-voice coding, and acoustic analyses. Standardized measures were used to cross-classify participants' speech and motor speech status. Compared to the 17.8% prevalence of four types of motor speech disorders reported in a study of 415 participants with idiopathic Speech Delay (SD), 47.7% of the present participants with CND met criteria for one of four motor speech disorders, including Speech Motor Delay (25.1%), Childhood
Dysarthria
(13.3%), Childhood Apraxia of Speech (4.3%), and concurrent Childhood
Dysarthria
and Childhood Apraxia of Speech (4.9%). Findings are interpreted to indicate a substantial prevalence of speech disorders, and notably, a substantial prevalence of motor speech disorders in persons with some types of CND. We suggest that diagnostic classification information from standardized motor speech assessment protocols can contribute to research in the pathobiologies of CND.
Abbreviations
: 16p: 16p11.2 deletion and duplication syndrome; 22q: 22q11.2 deletion syndrome; ASD: Autism
Spectrum
Disorder; CAS: Childhood Apraxia of Speech; CD: Childhood
Dysarthria
; CND: Complex Neurodevelopmental Disorder; DS: Down syndrome; FXS: Fragile X syndrome; GAL: Galactosemia; IID: Idiopathic Intellectual Disability; MSD: Motor Speech Disorder; No MSD: No Motor Speech Disorder; NSA: Normal(ized) Speech Acquisition; PEPPER: Programs to Examine Phonetic and Phonologic Evaluation Records; PSD: Persistent Speech Delay; PSE: Persistent Speech Errors; SD: Speech Delay; SDCS: Speech Disorders Classification System; SDCSS: Speech Disorders Classification System Summary; SE: Speech Errors; SMD: Speech Motor Delay; SSD: Speech Sound Disorders; TBI: Traumatic Brain Injury.
...
PMID:Estimates of the prevalence of speech and motor speech disorders in persons with complex neurodevelopmental disorders. 3122 Oct 12